About

Equinox Marker exists for people who need a calm, plainspoken way to orient themselves around a subject where stakes can be high and certainty can be limited. It is an independent reference about ibogaine safety, standards, and policy, built to make important context easier to locate and compare.

The resource is designed for people considering ibogaine, families, clinicians, researchers, policymakers, and others seeking safety-focused context. The safety standards hub provides the wider orientation, while the practical scope of our resource pathways shows how topics are organized for different questions.

We do not present a destination, provider, or protocol as a recommendation. Instead, we distinguish what a source says, what it does not establish, and what may require qualified medical, legal, or local guidance.

Equinox Marker groups material so readers can move between safety evidence, risk factors, protocols, regulatory developments, and the language used around treatment. This structure makes it easier to identify the difference between a general explanation and a decision that depends on personal or local facts.

Readers may encounter pages that compare the cost of ibogaine treatment in Mexico, summarize treatment discussions for addiction, or outline the claimed benefits of ibogaine therapy. These are context pages, not endorsements, medical advice, or assurances about suitability.

Other routes help readers question provider descriptions, such as an overview of an ibogaine clinic or a comparison of treatment-center selection criteria. Where a claim relies on terminology, we favor definitions that can be checked; the general definition of a clinical trial is one useful starting point for understanding why a study result may not apply outside its specific setting.

Equinox Marker is an independent information resource. It is not a clinic, medical provider, licensed treatment center, or legal authority, and it does not provide medical or legal advice. Readers should seek qualified guidance appropriate to their own circumstances before making decisions.

That boundary matters whether someone is reviewing discussions of ibogaine therapy for PTSD, reading clinical protocols, or trying to understand a regulatory development. We aim to make questions more precise, not to answer individualized health or legal questions on a reader’s behalf.

The resource remains useful when readers can trace statements back to their sources and recognize their limits. For medication and health information, the U.S. Food and Drug Administration’s drug information illustrates why official materials and individualized professional advice serve different purposes.